This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Stratasys (SSYS) Tests 3D Printed Models in Orthopedic Oncology
by Zacks Equity Research
Stratasys (SSYS) and Ricoh co-sponsor a clinical study comparing the efficacy of 3D-printed models to traditional CT or MRI scanning for bone tumor excision planning.
Is Materialise (MTLS) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Materialise (MTLS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Materialise (MTLS) delivered earnings and revenue surprises of -300% and 3.61%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Materialise (MTLS) Matches Q3 Earnings Estimates
by Zacks Equity Research
Materialise (MTLS) delivered earnings and revenue surprises of 0% and 0.54%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Materialise (MTLS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Materialise (MTLS) stock based on the movements in the options market lately.
Materialise (MTLS) Q2 Earnings Meet Estimates
by Zacks Equity Research
Materialise (MTLS) delivered earnings and revenue surprises of 0% and 4.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
i3 Verticals (IIIV) Soars 10.8%: Is Further Upside Left in the Stock?
by Zacks Equity Research
i3 Verticals (IIIV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks.com featured highlights include Madison Square Garden Entertainment, Materialise, InnovAge Holding, and Ligand Pharmaceuticals
by Zacks Equity Research
Madison Square Garden Entertainment, Materialise, InnovAge Holding, and Ligand Pharmaceuticals are part of zacks screen of the week article.
Detoxify Your Holdings by Steering Clear of These 4 Stocks
by Rimmi Singhi
Getting rid of fundamentally weak toxic stocks is important to shield your portfolio from losses. MSGE, MTLS, INNV and LGND are a few toxic stocks according to our model that you should dump now.
Materialise (MTLS) Reports Break-Even Earnings for Q1
by Zacks Equity Research
Materialise (MTLS) delivered earnings and revenue surprises of -100% and 2.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Materialise (MTLS) Stock Moves -1.45%: What You Should Know
by Zacks Equity Research
Materialise (MTLS) closed at $17.63 in the latest trading session, marking a -1.45% move from the prior day.
Cognyte Software Ltd. (CGNT) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Cognyte Software Ltd. (CGNT) delivered earnings and revenue surprises of -27.27% and 3.20%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?
Materialise (MTLS) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Materialise (MTLS) closed at $20.86 in the latest trading session, marking a +1.07% move from the prior day.
Materialise (MTLS) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Materialise (MTLS) delivered earnings and revenue surprises of 50% and 6.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Inseego (INSG) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inseego (INSG) delivered earnings and revenue surprises of -33.33% and 0.60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Materialise (MTLS) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Materialise's (MTLS) fourth-quarter 2021 earnings are likely to have benefited from solid operational performance in all three segments.
Materialise (MTLS) Stock Moves -1.5%: What You Should Know
by Zacks Equity Research
In the latest trading session, Materialise (MTLS) closed at $19.05, marking a -1.5% move from the previous day.
Materialise (MTLS) Stock Moves -0.25%: What You Should Know
by Zacks Equity Research
Materialise (MTLS) closed the most recent trading day at $20.35, moving -0.25% from the previous trading session.
Twilio (TWLO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Twilio (TWLO) delivered earnings and revenue surprises of 4.76% and 9.61%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Materialise (MTLS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Materialise (MTLS) closed at $20.32 in the latest trading session, marking a +1.04% move from the prior day.
Materialise (MTLS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Materialise (MTLS) closed the most recent trading day at $20.72, moving +1.02% from the previous trading session.
Materialise (MTLS) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Materialise (MTLS) closed at $18.38 in the latest trading session, marking a -1.08% move from the prior day.
Materialise (MTLS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Materialise (MTLS) closed the most recent trading day at $20.70, moving +0.68% from the previous trading session.
Zacks Industry Outlook Highlights: Pinterest, New Relic and Materialise
by Zacks Equity Research
Zacks Industry Outlook Highlights: Pinterest, New Relic and Materialise
3 Internet Software Stocks to Buy in a Challenging Industry
by Aniruddha Ganguly
The Zacks Internet software industry participants like Pinterest (PINS), New Relic (NEWR) and Materialise (MTLS) benefit from high demand for SaaS due to the increasing need for remote working, learning and diagnosis software as well as cybersecurity applications.